<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539266</url>
  </required_header>
  <id_info>
    <org_study_id>P07.058</org_study_id>
    <nct_id>NCT00539266</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia</brief_title>
  <acronym>ABC</acronym>
  <official_title>Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia A Double Blind, Placebo Controlled, Study in Diabetic and Non-diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose confirm and extend the findings of open studies on the apparent&#xD;
      efficacy of bone-marrow derived mononuclear cells for the induction of arteriogenesis in&#xD;
      patients with severe claudication or critical leg ischemia and pay special attention to the&#xD;
      influence of diabetic disease on the outcome of the study and to the possible&#xD;
      pro-atherogenic/ pro-inflammatory effects of BM-MNC injections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the safety and beneficial effects of intramuscular transplantation of bone marrow&#xD;
      derived mononuclear cells procedure appear well documented, a number of critical question&#xD;
      regarding application of BM-MNC for peripheral vascular disease remain to be answered. First,&#xD;
      although the original study has been partially performed as semi-blinded study (patients with&#xD;
      double sided claudication were recruited and blindly treated with BM-MNC in one leg and&#xD;
      peripheral blood injections in the other leg), this approach does exclude a placebo effect.&#xD;
      Second, although patients with mild diabetes were included in the protocol, the results for&#xD;
      diabetic patients were not analyzed separately. Diabetic disease is characterized by monocyte&#xD;
      and endothelial progenitor cell dysfunction and it is still unclear whether this approach is&#xD;
      also effective in diabetic patients. Third, although six-month results are reported long-term&#xD;
      efficacy has not been established yet.&#xD;
&#xD;
      To address these issues, the investigators now propose confirm and extend the findings from&#xD;
      open studies in a randomized double-blind study in patients with severe claudication or&#xD;
      critical leg ischemia and pay special attention to the influence of diabetic disease on the&#xD;
      outcome of the study and to the possible pro-atherogenic/ pro-inflammatory effects of BM-MNC&#xD;
      injections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Limb salvage/wound healing at t=6 months; Pain free walking distance</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life (RAND-36), pain Scores (Brief Pain Inventory), tcO2 (wrist/ankle ratio) ABI Collateral artery scores (angiogram) at t=6 months, Limb salvage/wound healing at t= 3 and 12 months, Pain free walking distance at t=3 and 12 months,</measure>
    <time_frame>3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Intermittent Claudication</condition>
  <condition>Peripheral Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non diabetic patients with Fontaine IIb-IV peripheral artery disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>non diabetic patients with Fontaine IIb-IV peripheral artery disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diabetic patients with Fontaine IIb-IV peripheral artery disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>diabetic patients with Fontaine IIb-IV peripheral artery disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bone marrow derived mononuclear cells</intervention_name>
    <description>40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>40 IM injections (calf muscle) of placebo suspension</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  persistent (&gt;3 months) disabling claudication (Fontaine's stages IIb or Rutherford's&#xD;
             categories 3, viz. pain free walking distance less than 100 meter) despite optimal&#xD;
             therapy or critical limb ischemia (Fontaine's stages III/IV or Rutherford's categories&#xD;
             4-6)&#xD;
&#xD;
          -  ineligibility for angioplasty or bypass procedures&#xD;
&#xD;
          -  male of female, &gt;18 years old&#xD;
&#xD;
          -  life expectancy &gt; 1 year&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  candidates for angioplasty or bypass procedures&#xD;
&#xD;
          -  inability to undergo bone marrow harvesting&#xD;
&#xD;
          -  any condition in the affected limb that is anticipated to require surgical&#xD;
             intervention in the first weeks after BM-MNC treatment&#xD;
&#xD;
          -  life threatening co-morbidity&#xD;
&#xD;
          -  poorly controlled diabetes (HbA1C &gt; 10%)&#xD;
&#xD;
          -  active malignancy in the 5 years prior to treatment&#xD;
&#xD;
          -  INR &gt;1.5 at the time of bone-marrow harvest&#xD;
&#xD;
          -  bleeding diathesis&#xD;
&#xD;
          -  inability to undergo arterial catheterization&#xD;
&#xD;
          -  inability to follow the protocol and to comply with the follow up requirements&#xD;
&#xD;
          -  any other conditions that, in the opinion of the investigators, could interfere with&#xD;
             the therapy or could pose a significant threat to the subject if the investigational&#xD;
             therapy was to be initiated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan HN Lindeman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan HN Lindeman, MD, PhD</last_name>
    <phone>#31 (0)71 5263968</phone>
    <email>Lindeman@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan HN Lindeman, MD, PhD</last_name>
      <phone>#31 (0)71 5263968</phone>
      <email>Lindeman@lumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>October 3, 2007</study_first_submitted>
  <study_first_submitted_qc>October 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2007</study_first_posted>
  <last_update_submitted>July 5, 2011</last_update_submitted>
  <last_update_submitted_qc>July 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Board of Directors</name_title>
    <organization>Leiden University Medical Centre</organization>
  </responsible_party>
  <keyword>Claudication</keyword>
  <keyword>Critical limb ischemia</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Bone marrow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

